[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361660-105":59,"doc-detail-361660-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-spatially-informed-mfishseq-assay-resolves-biomarker-discordance-and-predicts-treatment-response-in-breast-cancer","The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer","","Breast cancer’s complex biology and treatment selection are poorly served by existing assays that show only moderate subtype and risk reproducibility across platforms and tumor composition. An mFISHseq workflow is developed and validated on a retrospective cohort of 1082 female breast tissues, integrating multiplex RNA-FISH with RNA sequencing and laser capture microdissection to ensure tumor purity and quantify intratumoral heterogeneity. The method shows 93% accuracy versus immunohistochemistry, improves consensus subtyping and prognostication, and identifies high-risk patients with immune signatures predictive of response to neoadjuvant immunotherapy in I-SPY2, with a feasibility study supporting clinical potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-spatially-informed-mfishseq-assay-resolves-biomarker-discordance-and-predicts-treatment-response-in-breast-cancer/361660/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-spatially-informed-mfishseq-assay-resolves-biomarker-discordance-and-predicts-treatment-response-in-breast-cancer/361660.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does mFISHseq aim to solve in breast cancer biomarker testing?","Question",{"text":112,"@type":113},"It addresses biomarker discordance and limited predictive power by incorporating spatially resolved profiling that preserves tumor purity and heterogeneity rather than relying on bulk or crude macrodissection.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does mFISHseq combine different technologies?",{"text":117,"@type":113},"mFISHseq integrates multiplexed RNA fluorescent in situ hybridization with RNA sequencing, guided by laser capture microdissection to generate unbiased whole-transcriptome information from tumor-enriched regions.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports that mFISHseq can predict treatment response?",{"text":121,"@type":113},"The article reports 93% accuracy versus immunohistochemistry and shows that consensus subtyping and risk groups provide prognostic information and identify high-risk patients, including those with immune signatures predictive of response to neoadjuvant immunotherapy in the multicenter I-SPY2 trial.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361660,1791394758,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Article [https://doi.org/10.1038/s41467-024-55583-2](https://doi.org/10.1038/s41467-024-55583-2)  \nThe spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer  \nReceived: 1 July 2024  \n\n| Accepted: 16 December 2024 |\n| --- |\n| |\n| Check for updates |\n\nEvan D. Paul 1,2 , Barbora Huraiová 1,2, Natália Valková 1,2,  \nNatalia Matyasovska1,2,3, Daniela Gábrišová1,2, Soňa Gubová1,2,  \nHelena Ignačáková1,2, Tomáš Ondris 1,2, Michal Gala 1,2, Liliane Barroso1,2, Silvia Bendíková1,2, Jarmila Bíla1,2, Katarína Buranovská 1,2, Diana Drobná1,2, Zuzana Krchňáková1,2, Maryna Kryvokhyzha 1,2, Daniel Lovíšek1,2, Viktoriia Mamoilyk1,2, Veronika Mancikova1,2, Nina Vojtaššáková1,2, Michaela Ristová1,2,4, Iñaki Comino-Méndez 5, Igor Andrašina6,  \nPavel Morozov 7, Thomas Tuschl 7, Fresia Pareja 8 ,  \nJakob N. Kather 9,10,11  & Pavol Čekan1,2   \nCurrent assays fail to address breast cancer’s complex biology and accurately predict treatment response. On a retrospective cohort of 1082 female breast tissues, we develop and validate mFISHseq, which integrates multiplexed RNA ﬂuorescent in situ hybridization with RNA-sequencing, guided by laser capture microdissection. This technique ensures tumor purity, unbiased whole transcriptome proﬁling, and explicitly quantiﬁes intratumoral heterogeneity. Here we show mFISHseq has 93% accuracy compared to immunohistochemistry. Our consensus subtyping and risk groups mitigate single sample discordance, provide early and late prognostic information, and identify high risk patients with enriched immune signatures, which predict response to neoadjuvant immunotherapy in the multicenter, phase II, prospective I-SPY2 trial. We identify putative antibody-drug conjugate (ADC)-responsive patients, as evidenced by a 19-feature T-DM1 classiﬁer, validated on I-SPY2. Deploying mFISHseq as a research-use only test on 48 patients demonstrates clinical feasibility, revealing insights into the efﬁcacy of targeted therapies, like CDK4/  \n6 inhibitors, immunotherapies, and ADCs.  \nBreast cancer (BCa) is a heterogeneous disease with distinct biology leading to differences in response to treatment modalities and clinical outcomes1. The discovery of molecularly distinct subgroups of BCa (luminalA(LumA), luminalB(LumB), HER2-overexpressing(HER2-OE), basal- and normal-like)2–4 has fundamentally changed our understanding of BCa biology and paved the way for a union between genomic and clinical classiﬁcation of BCa subtypes. Various multigene signatures have emerged that provide important diagnostic,  \npredictive, and prognostic insights to inform appropriate treatment5,6. However, assignment of subtypes/risk groups show only moderate reproducibility at the individual tumor level depending on the array platform, tumor composition, and gene list and associated thresholds7–10. The underlying clinical and molecular factors driving discordance remain obscure, fostering uncertainty about which multigene prognostic signature to use and whether combining signatures improves performance.  \nA full list of afﬁliations appears at the end of the paper. e-mail: [paul@multiplexdx.com](paul@multiplexdx.com); [parejaf@mskcc.org](parejaf@mskcc.org); nikolas. kather@tu-dresden.de;  \n[pavol@multiplexdx.com](pavol@multiplexdx.com)  \nWith a rapidly expanding therapeutic arsenal, existing BCa biomarkers fail to accurately predict novel treatment response. Neoadjuvant immunotherapy is the new standard of care for high clinical risk TNBC regardless of PD-L1 status, which failed to predict response, leaving only clinical risk to stratify patients11. Ongoing trials(KEYNOTE- 765, CheckMate 7FL) aim to expand immunotherapies to hormone receptor positive (HR+)/HER2− patients in the neoadjuvant setting but patients are selected based on clinical risk and PD-L1 is only a secondary outcome measure. Identifying effective predictive biomarkers is critical in these early settings, especially in HR+/HER2− patients who","cbCainaOvdd2Obyy","https://ap.wps.com/l/cbCainaOvdd2Obyy","pdf",5070793,22,"English","# Background\n## Molecular subgroups and biomarker discordance\n## Immunotherapy and ADCs: unmet predictive needs\n## Spatial information as a missing dimension\n# Methods\n## Development of mFISHseq workflow\n## RNA-FISH panel and spatially guided sampling\n# Results\n## Accuracy vs immunohistochemistry\n## Consensus subtyping and risk stratification\n## Prognostic and predictive performance in I-SPY2\n# Clinical feasibility","[{\"question\":\"What problem does mFISHseq aim to solve in breast cancer biomarker testing?\",\"answer\":\"It addresses biomarker discordance and limited predictive power by incorporating spatially resolved profiling that preserves tumor purity and heterogeneity rather than relying on bulk or crude macrodissection.\"},{\"question\":\"How does mFISHseq combine different technologies?\",\"answer\":\"mFISHseq integrates multiplexed RNA fluorescent in situ hybridization with RNA sequencing, guided by laser capture microdissection to generate unbiased whole-transcriptome information from tumor-enriched regions.\"},{\"question\":\"What evidence supports that mFISHseq can predict treatment response?\",\"answer\":\"The article reports 93% accuracy versus immunohistochemistry and shows that consensus subtyping and risk groups provide prognostic information and identify high-risk patients, including those with immune signatures predictive of response to neoadjuvant immunotherapy in the multicenter I-SPY2 trial.\"}]","The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer | PDF",1790145209,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f860e9200e434d2904c7dbf49538507a.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec1e91194cf7dee7615e96271f053318.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3eb4f87e8598b0fd86aea7cd01db9b24.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bdce8fe8a0d872add192b9419a031ac.webp",980,1301]